+244.0%
EQIX vs GSK
+80.1%
+163.9%
-41.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.4% | 0.0% | +1.3% | +1.4% |
| 7D | +0.2% | -3.5% | +3.7% | +1.3% |
| 30D | -2.5% | -3.4% | +1.0% | -1.5% |
| 3M | 0.0% | -8.1% | +8.1% | +2.4% |
| 6M | +7.6% | -11.1% | +18.8% | +11.2% |
| YTD | +37.5% | +0.7% | +36.8% | +35.6% |
| 1Y | +32.9% | +20.1% | +12.8% | +22.5% |
| 3Y | +42.8% | +46.1% | -3.4% | +18.8% |
| 5Y | +35.8% | +48.2% | -12.4% | +9.8% |
| All | +244.0% | +80.1% | +163.9% | +163.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling